Web Analytics

3 Latest Announced Rounds

  • $67,000,000
    Series A
    Biotechnology Research
    Apr 2nd, 2025
  • $10,000,000
    Seed

    2 Investors

    Software Development
    Apr 2nd, 2025
  • $5,200,000
    Series A

    3 Investors

    Technology, Information and Internet
    Apr 2nd, 2025
$1,676.17M Raised in 53 Funding Rounds in the past 7 Days - View All

Funding Round Profile

GLOX Therapeutics Ltd.

start up
United Kingdom - Glasgow
  • 15/11/2023
  • Unknown
  • $5,362,000

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.


Related People

James ClarkCo Founder

James Clark United Kingdom - ND

Over the last twenty years Dr James Clark has held leadership positions within Precision Medicine companies including Response Genetics Inc., MDx Health, Enterome, Inivata, Enterobiotix Diadem, and Predictimmune. Most recently as CEO of Glox Therapeutics.

James has a proven track record in precision medicine, within medical device technology and product development in a number of diseases areas(oncology, microbiome, Inflammatory Bowel Disease and Alzheimer’s); as well as developing and implementing over ten successful commercial launches, with exceptional organisation/leadership skills and an extensive industry network.

James has developed over six laboratories in the US and Europe, holding Laboratory Director roles numerous times, and has led CLIA/CAP, ISO 15189 and ISO 13485 approvals

Since 2018 he has been part of the International Scientific Advisory Board for the ICCVs, focussing on the development of cancer vaccines.